Literature DB >> 25055834

Oral anticoagulation with rivaroxaban during pregnancy: a case report.

O Königsbrügge, M Langer, M Hayde, C Ay, I Pabinger1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25055834     DOI: 10.1160/TH14-04-0393

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  6 in total

1.  Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.

Authors:  M Hoeltzenbein; E Beck; K Meixner; C Schaefer; R Kreutz
Journal:  Clin Res Cardiol       Date:  2015-07-21       Impact factor: 5.460

2.  Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning.

Authors:  B Myers; R Neal; O Myers; M Ruparelia
Journal:  Obstet Med       Date:  2015-12-24

Review 3.  Use of medication for cardiovascular disease during pregnancy.

Authors:  Petronella G Pieper
Journal:  Nat Rev Cardiol       Date:  2015-12       Impact factor: 32.419

4.  Reproductive issues in women on direct oral anticoagulants.

Authors:  Jan Beyer-Westendorf; Sandra Marten
Journal:  Res Pract Thromb Haemost       Date:  2021-05-03

Review 5.  Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.

Authors:  Allison E Burnett; Charles E Mahan; Sara R Vazquez; Lynn B Oertel; David A Garcia; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

Review 6.  Special Considerations for Women of Reproductive Age on Anticoagulation.

Authors:  Tali Azenkot; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2022-05-31       Impact factor: 6.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.